400 related articles for article (PubMed ID: 29864682)
1. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.
Chen LH; Wang YF; Xu QH; Chen SS
Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302
[TBL] [Abstract][Full Text] [Related]
3. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
[TBL] [Abstract][Full Text] [Related]
4. Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation.
Spahis S; Alvarez F; Dubois J; Ahmed N; Peretti N; Levy E
Prostaglandins Leukot Essent Fatty Acids; 2015 Aug; 99():25-34. PubMed ID: 26066299
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study.
Parker HM; O'Connor HT; Keating SE; Cohn JS; Garg ML; Caterson ID; George J; Johnson NA
Br J Nutr; 2015 Sep; 114(5):780-7. PubMed ID: 26202539
[TBL] [Abstract][Full Text] [Related]
7. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
[TBL] [Abstract][Full Text] [Related]
8. n-3 polyunsaturated fatty acids in phospholipid or triacylglycerol form attenuate nonalcoholic fatty liver disease via mediating cannabinoid receptor 1/adiponectin/ceramide pathway.
Chen YF; Fan ZK; Gao X; Zhou F; Guo XF; Sinclair AJ; Li D
J Nutr Biochem; 2024 Jan; 123():109484. PubMed ID: 37866428
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease.
Boyraz M; Pirgon Ö; Dündar B; Çekmez F; Hatipoğlu N
J Clin Res Pediatr Endocrinol; 2015 Jun; 7(2):121-7. PubMed ID: 26316434
[TBL] [Abstract][Full Text] [Related]
10. A high ratio of dietary n-3/n-6 polyunsaturated fatty acids improves obesity-linked inflammation and insulin resistance through suppressing activation of TLR4 in SD rats.
Liu HQ; Qiu Y; Mu Y; Zhang XJ; Liu L; Hou XH; Zhang L; Xu XN; Ji AL; Cao R; Yang RH; Wang F
Nutr Res; 2013 Oct; 33(10):849-58. PubMed ID: 24074743
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
[TBL] [Abstract][Full Text] [Related]
12. Long chain omega-3 polyunsaturated fatty acids in pediatric metabolic syndrome.
Pacifico L; Giansanti S; Gallozzi A; Chiesa C
Mini Rev Med Chem; 2014; 14(10):791-804. PubMed ID: 25307311
[TBL] [Abstract][Full Text] [Related]
13. Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate hepatic pathology.
Khadge S; Sharp JG; Thiele GM; McGuire TR; Klassen LW; Duryee MJ; Britton HC; Dafferner AJ; Beck J; Black PN; DiRusso CC; Talmadge J
J Nutr Biochem; 2018 Feb; 52():92-102. PubMed ID: 29175671
[TBL] [Abstract][Full Text] [Related]
14. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Parker HM; Johnson NA; Burdon CA; Cohn JS; O'Connor HT; George J
J Hepatol; 2012 Apr; 56(4):944-51. PubMed ID: 22023985
[TBL] [Abstract][Full Text] [Related]
16. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation.
Yang J; Fernández-Galilea M; Martínez-Fernández L; González-Muniesa P; Pérez-Chávez A; Martínez JA; Moreno-Aliaga MJ
Nutrients; 2019 Apr; 11(4):. PubMed ID: 31003450
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
Nobili V; Alisi A; Musso G; Scorletti E; Calder PC; Byrne CD
Crit Rev Clin Lab Sci; 2016; 53(2):106-20. PubMed ID: 26463349
[TBL] [Abstract][Full Text] [Related]
18. Carotid intima-media thickness and flow-mediated dilation in obese children with non-alcoholic fatty liver disease.
Torun E; Aydın S; Gökçe S; Özgen İT; Donmez T; Cesur Y
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():92-8. PubMed ID: 25910377
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Spooner MH; Jump DB
Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials.
Guo XF; Yang B; Tang J; Li D
Clin Nutr; 2018 Feb; 37(1):113-122. PubMed ID: 28161092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
